DAIICHI SANKYO acquires osteoporosis medication EVISTA® from Lilly

DAIICHI SANKYO CompanyThe Japanese pharmaceutical company DAIICHI SANKYO Group has purchased the European rights to the osteoporosis medication EVISTA® from the U.S. Company Eli Lilly and Company. In the process, the company is planning to gain additional sales volume of approximately €80 million.

"By purchasing these rights, we are pressing ahead with our expansion strategy in Europe and have taken another major step toward our goal of achieving at least €1 billion in sales by no later than 2011," said Reinhard Bauer, CEO of DAIICHI SANKYO EUROPE GmbH. But, Bauer noted this was only an interim objective. "By 2015, we intend to be one of the leading research-focused pharmaceutical companies in Europe," he added.

In 2006, the marketing and distribution rights to EVISTA® in six European countries, including Germany, Italy, Belgium, Netherlands, Switzerland and Austria were granted to DAIICHI SANKYO. The latest agreement covers the remaining countries in Europe, with the exception of Greece, where Lilly will continue to market the product with its joint venture company Pharmaserve. The recent agreement is subject to the approval of the competent antitrust authorities.

The agreement represents an expansion of the partnership between DAIICHI SANKYO and Eli Lilly and Company. Both companies are already working jointly on Prasugrel, an oral antiplatelet agent originally developed by DAIICHI SANKYO.

About DAIICHI SANKYO Company, Limited
DAIICHI SANKYO Company, Limited, established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator, continuously generating innovative drugs that enrich the quality of life for patients around the world. The company uses its cumulative knowledge and expertise in the fields of cardiovascular disease, cancer, metabolic disorders, and infection as a foundation for developing an abundant product lineup and R&D pipeline. For more information, visit www.daiichi-sankyo.eu.

Most Popular Now

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...

Pfizer reaches a global agreement with AbbVie

Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under ...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

GSK reaches agreement to acquire TESARO, an oncolo…

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...